ACAD News and Press, ACADIA Pharmaceuticals Inc. From 10/21/25

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Canada NewsWire Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER , Oct. 21, 2025 /CNW/ --  Equity Insider News Commentary – Conventi...

Company to host conference call and webcast on Wednesday, November 5, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financi...

2025-10-06 07:30:00 ET Read the full article on Seeking Alpha For further details see: ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish

2025-10-03 09:46:13 ET DENVER, Colo., Oct 03, 2025 ( 247marketnews.com )- Markets are trading with conviction this morning as tech, media, and entertainment names push forward on news catalysts. Here’s what’s driving the tape: Rumble (NASDAQ:RUM) announced a stra...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson’s Disease and Movement Disorders ® being held October 5-9, 2025, in Honolulu, Hawaii. ...

2025-09-24 15:22:13 ET Investment Overview Earlier this year - on February 13th, to be precise, in a note for Seeking Alpha I switched my Sell rating on Acadia Pharmaceuticals Inc. ( ACAD ) stock to a Buy.... Read the full article on Seeking Alpha For further det...

A look at the top 10 most actives in the United States Youxin Technology Ltd (YAAS) rose 53.9% to $0.115 on volume of 462,438,399 shares AtlasClear Holdings Inc. (ATCH) rose 56.1% to $0.6243 on volume of 98,005,042 shares Erayak Power Solution Group Inc. (RAYA) rose 21.7% to $0.0747 on volu...

2025-09-24 08:05:58 ET More on Acadia Pharma, Soleno Therapeutics Soleno Therapeutics: Patient Death Unrelated To Vykat, But Safety Concerns May Undermine Launch ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcrip...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS). Intranasal carbetocin did not demonstrate a statistical...

2025-09-15 20:21:09 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 08/14/2025. The 13F portfolio value in...